Katar, MuzafferGevrek, FikretFırat, FatihUnsal, VelıdTapar, HakanKaraman, TugbaKuyucu, Yunus Emre2025-02-152025-02-1520241303-829X1303-829Xhttps://doi.org/10.1515/tjb-2024-0111https://search.trdizin.gov.tr/en/yayin/detay/1359382/possible-protective-effect-of-remifentanil-against-testicular-ischemia-reperfusion-injuryObjectives: This study aims to evaluate the protective effi- cacy of remifentanil against testicular ischemia-reperfusion injury. Methods: The study included 24 male rats. The rats were randomized into three groups: Group 1 was the control group. Group 2 was subjected to a testicular torsion/ detorsion model. Group 3 underwent similar procedures and additionally received remifentanil (0.6 μg/kg/min) intrave- nously for the first 20 min of reperfusion. Blood samples were taken for biochemical analyses, and orchiectomy was performed for histopathologic examination. Results: Biochemical analysis of blood samples showed a significant increase in antioxidant enzyme activity, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in Group 3 compared to Group 2 (p:0.004 and p:0.002, respectively). There was a dramatic decrease in the levels of proinflammatory cytokines, including interleukin-1 beta (IL-1 Beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in Group 3 compared to Group 2 (p:0.001, p:0.046, and p:0.004, respectively). Similarly, malondialdehyde (MDA) levels decreased in Group 3 compared to Group 2 (p:0.004). Histopathologic examination of Group 3 rats showed positive changes in inflammation, hemorrhage, edema, and conges- tion levels compared to Group 2 (p<0.001). Similarly, there was a positive effect on the Johnsen and Cosentino score in Group 3 compared to Group 2 (p:0.001 and p<0.001, respectively). Conclusions: In our study, it has been documented that remifentanil protects against testicular ischemia-reperfusion injury.en10.1515/tjb-2024-0111info:eu-repo/semantics/openAccessRemifentanilTestisIschemia-Reperfusion InjuryArticle2-s2.0-85204802867